ALSO NOTED: Medicines Company gets not approvable letter; Sun, Taro merger called off; and much more...

> The Medicines Company got a not approvable letter on an sNDA for an additional dosing regimen for Angiomax, a treatment of acute coronary syndromes initiated in the emergency department. Release

> A planned merger between Sun Pharmaceuticals and Taro Pharmaceuticals has been canceled. Taro's board decided that it wasn't in the best interest of the company. Taro release

> NeoStem execs say they don't know why the company's stock has declined over the last four days. NeoStem release

> New research has highlighted a brain protein called DARPP-32 which bolsters the well-documented dopamine response. It could alter long-lasting responses to drugs of abuse, and decreases motivation for food reward. Report

> Networking tools like Facebook and Twitter will soon be de rigeur for pharma marketing, replacing blogs as the must-use online tools. Report

> New U.K. guidelines for heart-attack prevention could be a major windfall for statin-makers. Report

> Say hello to Pfizer's new general counsel, Amy Schulman (photo), a top litigator who's served as lead attorney on the company's Celebrex and Bextra cases. Report

And Finally... Here's a quandary: You're a good-sized drugmaker, but not a behemoth able to throw your weight around the industry's big trade associations. So how do you get your voice heard in our nation's capital? Form your own association, of course. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.